Vaccine accessibility has been limited for patients impacted by health disparities and social determinants of health (SDoH).
James Lewis, PharmD, FIDSA:Barriers to vaccine access as related to social determinants of health have come to the forefront during the COVID-19 pandemic. We and a lot of other health care institutions tried to find ways to improve that access. For example, our institution [Oregon Health & Science University] developed several mobile platforms, including vans that went around to certain parts of the city; worked with certain groups, such as churches or other community organizations; and served a lot of populations that have historically been underserved medically. We tried to work with them to develop outreach programs where we were able to do vaccinations on-site. We took the vaccines to them. I don’t know if that type of process is sustainable going forward, but it is a nice model for health care institutions and can provide novel ways to get to some of these populations.
A major learning point for me, during all this, was that a lot of the groups we approached as an organization were receptive. Churches, in particular, stepped up and were phenomenal about getting the word out. A lot of other organizations were extremely impressive as well, messaging their members, “This is when it’s going to be available. We encourage you to do it. Come on out.” We got a very good turnout. Early in the COVID-19 pandemic, everybody wanted that vaccine. I’m not as optimistic that those numbers look as good compared with other vaccines, which were perceived to be less urgent. But it would be a lot better than we currently do in some of these populations. How to balance the best use of resources in this population is a discussion that’s going to take people much smarter than I to figure out.
The way we tried to limit some of the disparities in cultural and ethnic groups was the structure with regard to going to those populations. At our clinics in areas where a lot of underserved populations have lived, we went out of our way to make sure there were adequate resources, and an ample supply of vaccine…. It’s an area in which we continue to struggle in the United States. But the recognition of the challenge is a big part of it. If you don’t know that there’s a problem, you can’t fix it. We’re at a point where we know that there’s a problem. The data consistently show us that this is an issue, and how to best improve things. It’s an open-ended question. It will be interesting, over the next few years, to see how programs such as ours impacted populations that are historically underserved. Did it improve compared with historical norms? Administrators and policymakers want to know because they’re obviously looking for processes that work in this population. The data for what works in scenarios like this are unfortunately very thin.
Transcript edited for clarity.
FDA Approves Two RSV Vaccines for Older Adults, and an Advisory Panel Recommended Another to Protect InfantsJune 1st 2023
Respiratory syncytial virus (RSV) can be deadly for the very young and the old and frail. GSK's vaccine will be marketed under the brand name Arexvy and Pfizer's under the name Abrysvo.
Name Change Needed for Vaccine Adverse Event Reporting System to Reduce Misinformation, Says Penn’s Annenberg CenterMay 27th 2023
The purpose of the federal vaccine safety reporting system often is misunderstood, and its data can be easily used to spread false information about vaccination. A new report from the Annenberg Public Policy Center at the University of Pennsylvania looks at how it was manipulated to raise doubts about COVID-19 vaccines and suggests remedies.
A Universal Flu Vaccine: The Dream Inches Just A Bit Closer to RealityMay 19th 2023
Seasonal influenza kills hundreds of thousands of people every year due to a constantly changing virus and highly inefficient vaccine production. A universal flu vaccine could deal with the first problem, and mRNA technology with the second.
Ghana is First To Approve ‘World-Changing’ Malaria VaccineMay 3rd 2023
Researchers have spent a century trying to develop a vaccine against malaria, one of the world’s biggest killers. The first shot to be approved, two years ago, is 30% effective. A new one, in the works for three decades, has a reported 77% efficacy and a licensee with the capacity to produce 200 million doses a year.
CDC Streamlines COVID-19 Vaccination Recommendations: One Shot for Adults Under 65, Two for SeniorsApril 24th 2023
The federal government is hoping that newly simplified vaccination guidelines will lead more Americans to get vaccinated against COVID-19. In other pandemic news, HHS announced plans to keep vaccines and treatments free for the uninsured, and an appellate court sided with the Biden administration's disputed vaccination requirement for federal contractors.
Vaccines to Protect the Young and the Old Against RSV Show Promising Results in Phase 3 trialsApril 13th 2023
Despite decades of research, no available vaccine targets respiratory syncytial virus (RSV), a disease that causes hundreds of thousands of deaths worldwide among young children and older adults. Interim results of two late-stage trials of Pfizer’sRSV prefusion F vaccine suggest the vaccine is efficacious, although the low RSV infection rates during the high COVID-19 pandemic years limited some of the findings.
2 Clarke Drive
Cranbury, NJ 08512